PHAT Phathom Pharmaceuticals, Inc. - Common Stock
NASDAQ · Pharmaceuticals · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 七月 30, 2026
$6.92
· % 处于52周区间
· 高于低点
· 至高点
$6.8252周低点
$18.3152周高点
市值 (MRQ)
$554M
P/E (TTM)
-5.5
EPS (TTM)
$-1.25
收入 (TTM)
$240M
PHAT 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$6.92
市值 (MRQ)
$554M
P/E (TTM)
-5.5
EPS (TTM)
$-1.25
收入 (TTM)
$240M
ROE (TTM)
26.4%
负债/权益 (MRQ)
-0.5
52周区间
$7–$18
PHAT 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
10年表现 收入、净利润、利润率和每股收益趋势
收入$175M2022-12-31 → 2025-12-31
EPS$-3.032021-12-31 → 2025-12-31
自由现金流$-167M2019-12-31 → 2025-12-31
净利率-41.3%2023-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | PHAT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | -5.55年均值 ≈-3.3 | ≈-3.3 | · | · | |
| P/S (TTM) | 2.35年均值 ≈263.8 | ≈263.8 | 2.7 | 价格较高 | |
| 市净率 (MRQ) | -1.65年均值 ≈-1.9 | ≈-1.9 | · | · | |
| EV / EBITDA (企业价值 / EBITDA) | -3.95年均值 ≈-3.4 | ≈-3.4 | · | · | |
| 股价/自由现金流 (TTM) | -15.05年均值 ≈-4.0 | ≈-4.0 | · | · | |
| 市现率 (TTM) | -15.15年均值 ≈-4.0 | ≈-4.0 | · | · | |
| EV / Revenue (市值/营收) | 3.65年均值 ≈144.3 | ≈144.3 | · | · | |
| EV / FCF (市值/自由现金流) | -3.85年均值 ≈-3.4 | ≈-3.4 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | PHAT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 毛利率 (TTM) | 82.9%5年均值 ≈82.7% | ≈82.7% | 71.8% | 顶尖 | |
| 营业利润率 (TTM) | -17.0%5年均值 ≈-8375.4% | ≈-8375.4% | -1.8% | 低于平均水平 | |
| 息税折旧摊销前利润率 (TTM) | -16.7%5年均值 ≈-8346.7% | ≈-8346.7% | 1.8% | 弱 | |
| Pretax Margin (税前利润率) | -126.4% | · | -6.8% | 弱 | |
| 净利润率 (TTM) | -41.3%5年均值 ≈-10096.8% | ≈-10096.8% | -7.5% | 弱 | |
| ROA (TTM) | -34.3%5年均值 ≈-78.9% | ≈-78.9% | -15.7% | 弱 | |
| ROE (TTM) | 26.4%5年均值 ≈175.3% | ≈175.3% | 52.3% | 持平 | |
| ROIC | 69.8% | · | 40.3% | 顶尖 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | PHAT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | -0.55年均值 ≈-0.6 | ≈-0.6 | 0.0 | 低负债 | |
| 流动比率 (MRQ) | 1.95年均值 ≈6.4 | ≈6.4 | 3.0 | 低流动性 | |
| Quick Ratio (速动比率) | 1.65年均值 ≈6.2 | ≈6.2 | 2.0 | 持平 | |
| 长期负债/股东权益 (MRQ) | -0.55年均值 ≈-0.6 | ≈-0.6 | 0.0 | 低负债 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | PHAT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 216.9% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | PHAT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.55年均值 ≈0.2 | ≈0.2 | 0.5 | 顶尖 | |
| Inventory Turnover (库存周转率) | 5.25年均值 ≈3.0 | ≈3.0 | 3.0 | 顶尖 | |
| Receivables Turnover (应收账款周转率) | 3.05年均值 ≈2.2 | ≈2.2 | 3.5 | 弱 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$472.0K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
7.7%
下次报告
十月 28, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 5, 2026 | $-0.21 | $-0.26 | 18.1% |
| 2026年3月31日 | 五月 12, 2026 | $-0.37 | $-0.33 | -12.6% |
| 2025年12月31日 | $-0.29 | $-0.39 | 25.5% | |
| 2025年9月30日 | $-0.41 | $-0.56 | 26.2% | |
| 2025年6月30日 | $-1.05 | $-1.06 | 1.0% | |
| 2025年3月31日 | $-1.31 | $-1.17 | -12.0% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $175M | $55M | $682.0K | $0 | |
| Cost of Revenue | $23M | $8M | $167.0K | $0 | |
| Gross Profit | $153M | $47M | $515.0K | $0 | |
| R&D Expense | $33M | $34M | $50M | $71M | |
| SG&A Expense | $280M | $291M | $118M | $101M | |
| Operating Expenses | $312M | $325M | $168M | $172M | |
| Operating Income | $-160M | $-277M | $-167M | $-172M | |
| Interest Expense | · | · | $42M | $27M | |
| Interest Income | $7M | $15M | $8M | $2M | |
| Other Non-op | $-190.0K | $-8.0K | $-188.0K | $-110.0K | |
| Pretax Income | $-221M | $-334M | · | · | |
| Income Tax | $0 | $0 | $0 | $0 | |
| Net Income | $-221M | $-334M | $-202M | $-198M | |
| EPS (Basic) | $-3.03 | $-5.29 | $-3.93 | $-5.05 | |
| EPS (Diluted) | $-3.03 | $-5.29 | $-3.93 | $-5.05 | |
| Shares (Basic) | 72,918,764 | 63,176,210 | 51,289,092 | 39,118,215 | |
| Shares (Diluted) | 72,918,764 | 63,176,210 | 51,289,092 | 39,118,215 | |
| EBITDA | $-159M | $-277M | $-167M | $-172M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | $130M | $297M | $381M | $155M | |
| Receivables | $78M | $39M | $2M | $0 | |
| Inventory | $6M | $3M | $1M | $0 | |
| Prepaid Expense | $15M | $21M | $13M | $5M | |
| Current Assets | $229M | $360M | $397M | $161M | |
| PP&E (Net) | $1M | $1M | $2M | $1M | |
| PP&E (Gross) | $5M | $4M | $4M | $3M | |
| Accum. Depreciation | $3M | $3M | $2M | $1M | |
| Other Non-current Assets | $3M | $2M | $2M | $299.0K | |
| Total Assets | $259M | $378M | $414M | $165M | |
| Accounts Payable | $5M | $11M | $13M | $10M | |
| Accrued Liabilities | $90M | $53M | $17M | $15M | |
| Current Liabilities | $132M | $86M | $39M | $26M | |
| Capital Leases | $2M | · | $462.0K | $1M | |
| Other Non-current Liabilities | $4M | $12M | $10M | $8M | |
| Total Liabilities | $697M | $632M | $487M | $240M | |
| Long-term Debt | $209M | $201M | $138M | $95M | |
| Total Debt | $209M | $201M | $138M | $95M | |
| Common Stock | $6.0K | $6.0K | $5.0K | $3.0K | |
| Retained Earnings | $-1.48B | $-1.26B | $-929M | $-727M | |
| Treasury Stock | $0 | $0 | $0 | $0 | |
| Stockholders' Equity | $-438M | $-254M | $-73M | $-75M | |
| Liabilities + Equity | $259M | $378M | $414M | $165M | |
| Shares Outstanding | 71,419,025 | 68,518,238 | 57,970,044 | 41,468,871 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| D&A | $633.0K | $795.0K | $575.0K | $620.0K | |
| Stock-based Comp | $29M | $24M | $45M | $24M | |
| Other Non-cash | $25M | $43M | $18M | $26M | |
| Operating Cash Flow | $-167M | $-267M | $-138M | $-147M | |
| CapEx | $229.0K | $135.0K | $2M | $1M | |
| Investing Cash Flow | $-229.0K | $-135.0K | $-2M | $-1M | |
| Debt Issued | $0 | $59M | $39M | $0 | |
| Net Debt Issued | $0 | $59M | $39M | · | |
| Stock Issued | · | · | $14M | · | |
| Financing Cash Flow | $-288.0K | $183M | $368M | $120M | |
| Net Change in Cash | $-167M | $-84M | $228M | $-28M | |
| Free Cash Flow | $-167M | $-267M | $-139M | $-148M |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Gross Margin | 87.1% | 85.6% | 75.5% | · | |
| Operating Margin | -91.4% | -502.2% | -24532.5% | · | |
| Net Margin | -126.4% | -605.1% | -29558.9% | · | |
| Pretax Margin | -126.4% | · | · | · | |
| EBITDA Margin | -91.0% | -500.8% | -24448.2% | · | |
| ROA | -69.4% | -84.4% | -69.7% | -111.6% | |
| ROE | 52.4% | 151.7% | 445.4% | 390.6% | |
| ROIC | 69.8% | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Current Ratio | 1.7 | 4.2 | 10.2 | 6.1 | |
| Quick Ratio | 1.6 | 3.9 | 9.9 | 5.9 | |
| Debt / Equity | -0.5 | -0.8 | -1.9 | -1.3 | |
| LT Debt / Equity | -0.5 | -0.8 | -1.9 | -1.3 | |
| Interest Coverage | · | · | -4.0 | -6.3 |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.1 | 0.0 | · | |
| Inventory Turnover | 5.2 | 3.6 | 0.3 | · | |
| Receivables Turnover | 3.0 | 2.7 | 0.8 | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Book Value / Share | $-6.14 | $-4.37 | $-1.26 | $-1.80 | |
| Revenue / Share | $2.40 | $0.87 | $0.01 | · | |
| Cash Flow / Share | $-2.29 | $-4.22 | $-2.68 | $-3.75 | |
| Cash / Share | $1.82 | $5.13 | $6.58 | $3.75 | |
| EPS (TTM) | $-3.03 | $-5.29 | $-3.93 | $-5.05 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue YoY | 216.9% | 8001.5% | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue TTM | $175M | $55M | $682.0K | $0 | |
| Net Income TTM | $-221M | $-334M | $-202M | $-198M | |
| Market Cap | $1.18B | $471M | $529M | $465M | |
| Enterprise Value | $1.26B | $375M | $286M | $405M | |
| P/E | -5.5 | -1.5 | -2.3 | -2.2 | |
| P/S | 6.8 | 8.5 | 776.1 | · | |
| P/B | -2.7 | -1.9 | -7.3 | -6.2 | |
| P / Cash Flow | -7.1 | -1.8 | -3.8 | -3.2 | |
| P / FCF | -7.1 | -1.8 | -3.8 | -3.2 | |
| EV / EBITDA | -7.9 | -1.4 | -1.7 | -2.4 | |
| EV / FCF | -7.6 | -1.4 | -2.1 | -2.7 | |
| EV / Revenue | 7.2 | 6.8 | 418.9 | · | |
| Earnings Yield | -18.3% | -65.1% | -43.0% | -45.0% |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $74M | $58M | $58M | $50M | $40M | $29M | $30M | $16M | $7M | $2M | $682.0K | $0 | $0 | $0 | |
| Cost of Revenue | $15M | $12M | $8M | $6M | $5M | $4M | $4M | $2M | $1M | $426.0K | $167.0K | $0 | $0 | $0 | |
| Gross Profit | $59M | $46M | $50M | $43M | $34M | $25M | $26M | $14M | $6M | $1M | $515.0K | $0 | $0 | $0 | |
| R&D Expense | $8M | $8M | $7M | $7M | $9M | $9M | $9M | $9M | $7M | $9M | $13M | $12M | $13M | $11M | |
| SG&A Expense | $55M | $54M | $48M | $52M | $85M | $94M | $77M | $76M | $76M | $62M | $57M | $23M | $19M | $19M | |
| Operating Expenses | $63M | $62M | $56M | $59M | $94M | $104M | $85M | $85M | $83M | $71M | $70M | $36M | $32M | $30M | |
| Operating Income | $-4M | $-15M | $-6M | $-15M | $-60M | $-79M | $-59M | $-71M | $-77M | $-70M | $-70M | $-36M | $-32M | $-30M | |
| Interest Expense | · | · | · | · | · | · | · | · | $18M | $17M | · | $10M | $10M | $9M | |
| Interest Income | $2M | $2M | $1M | $1M | $2M | $3M | $4M | $4M | $4M | $4M | $3M | $3M | $348.0K | $1M | |
| Other Non-op | $-24.0K | $-831.0K | $-6.0K | $-7.0K | $-155.0K | $-22.0K | $49.0K | $-8.0K | $-6.0K | $-43.0K | $-14.0K | $-197.0K | $3.0K | $20.0K | |
| Net Income | $-18M | $-30M | $-21M | $-30M | $-76M | $-94M | $-74M | $-86M | $-91M | $-83M | $-80M | $-43M | $-41M | $-38M | |
| EPS (Basic) | $-0.21 | $-0.37 | $-0.26 | $-0.41 | $-1.05 | $-1.31 | $-0.99 | $-1.32 | $-1.56 | $-1.42 | $-1.44 | $-0.76 | $-0.84 | $-0.89 | |
| EPS (Diluted) | $-0.21 | $-0.37 | $-0.26 | $-0.41 | $-1.05 | $-1.31 | $-0.99 | $-1.32 | $-1.56 | $-1.42 | $-1.44 | $-0.76 | $-0.84 | $-0.89 | |
| Shares (Basic) | 83,747,104 | 82,050,618 | · | 73,396,435 | 72,466,203 | 71,969,411 | · | 64,627,847 | 58,558,145 | 58,371,480 | · | 56,782,379 | 48,500,516 | 42,354,520 | |
| Shares (Diluted) | 83,747,104 | 82,050,618 | · | 73,396,435 | 72,466,203 | 71,969,411 | · | 64,627,847 | 58,558,145 | 58,371,480 | · | 56,782,379 | 48,500,516 | 42,354,520 | |
| EBITDA | $-4M | $-15M | · | $-15M | $-60M | $-79M | · | $-71M | $-77M | $-70M | · | $-36M | $-32M | $-30M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $181M | $130M | $135M | $150M | $212M | $297M | $335M | $276M | $322M | $381M | $214M | $249M | $130M | |
| Receivables | $97M | $81M | $78M | $56M | $51M | $36M | $39M | $21M | $11M | $4M | $2M | · | · | · | |
| Inventory | $8M | $7M | $6M | $4M | $3M | $3M | $3M | $3M | $2M | $1M | $1M | $111.0K | $111.0K | · | |
| Prepaid Expense | $8M | $8M | $15M | $13M | $15M | $13M | $21M | $15M | $15M | $13M | $13M | $13M | $9M | $10M | |
| Current Assets | $296M | $277M | $229M | $208M | $219M | $265M | $360M | $374M | $305M | $340M | $397M | $227M | $258M | $140M | |
| PP&E (Net) | $971.0K | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | |
| PP&E (Gross) | · | · | $5M | · | · | · | $4M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | |
| Accum. Depreciation | · | · | $3M | · | · | · | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Other Non-current Assets | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $4M | $4M | $299.0K | |
| Total Assets | $327M | $305M | $259M | $240M | $250M | $294M | $378M | $387M | $319M | $356M | $414M | $237M | $265M | $144M | |
| Accounts Payable | $5M | $6M | $5M | $1M | $4M | $12M | $11M | $7M | $8M | $8M | $13M | $6M | $4M | $5M | |
| Accrued Liabilities | $109M | $83M | $90M | $65M | $64M | $43M | $53M | $36M | $27M | $17M | $17M | $13M | $15M | $8M | |
| Current Liabilities | $154M | $125M | $132M | $93M | $92M | $74M | $86M | $65M | $47M | $43M | $39M | $24M | $22M | $14M | |
| Capital Leases | $2M | $2M | $2M | $2M | $589.0K | $0 | · | $0 | $133.0K | $292.0K | $462.0K | $628.0K | $789.0K | $945.0K | |
| Other Non-current Liabilities | $4M | $4M | $4M | $12M | $12M | $12M | $12M | $11M | $10M | $10M | $10M | $8M | $8M | $8M | |
| Total Liabilities | $671M | $642M | $697M | $663M | $656M | $633M | $632M | $574M | $553M | $505M | $487M | $255M | $247M | $234M | |
| Long-term Debt | $165M | $164M | $209M | $207M | $205M | $203M | $201M | $176M | $174M | $149M | $138M | $99M | $98M | $97M | |
| Total Debt | $165M | $164M | · | $207M | $205M | $203M | · | $176M | $174M | $149M | · | $99M | $98M | $97M | |
| Common Stock | $8.0K | $7.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $4.0K | |
| Retained Earnings | $-1.53B | $-1.51B | $-1.48B | $-1.46B | $-1.43B | $-1.36B | $-1.26B | $-1.19B | $-1.10B | $-1.01B | $-929M | $-849M | $-806M | $-765M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Stockholders' Equity | $-344M | $-337M | $-438M | $-423M | $-406M | $-338M | $-254M | $-187M | $-234M | $-149M | $-73M | $-18M | $18M | $-90M | |
| Liabilities + Equity | $327M | $305M | $259M | $240M | $250M | $294M | $378M | $387M | $319M | $356M | $414M | $237M | $265M | $144M | |
| Shares Outstanding | 80,070,048 | 79,442,367 | 71,419,025 | 71,043,149 | 70,104,419 | 69,638,070 | 68,518,238 | 68,323,938 | 58,601,025 | 58,524,101 | 57,970,044 | 56,809,085 | 56,639,085 | 43,571,140 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $114.0K | $110.0K | $128.0K | $156.0K | $172.0K | $177.0K | $193.0K | $191.0K | $197.0K | $214.0K | $185.0K | $121.0K | $123.0K | $146.0K | |
| Stock-based Comp | $7M | $6M | $6M | $9M | $8M | $6M | $7M | $6M | $6M | $6M | $25M | $6M | $7M | $7M | |
| Other Non-cash | · | $9M | · | · | · | $4M | · | · | · | $8M | · | · | · | $-9M | |
| Operating Cash Flow | $-2M | $-16M | $-5M | $-14M | $-63M | $-85M | $-63M | $-64M | $-71M | $-69M | $-44M | $-32M | $-22M | $-40M | |
| CapEx | $44.0K | $61.0K | $87.0K | $27.0K | $97.0K | $18.0K | $5.0K | $44.0K | $46.0K | $40.0K | $475.0K | $939.0K | $6.0K | $214.0K | |
| Investing Cash Flow | $-44.0K | $-61.0K | $-87.0K | $-27.0K | $-97.0K | $-18.0K | $-5.0K | $-44.0K | $-46.0K | $-40.0K | $-475.0K | $-939.0K | $-6.0K | $-214.0K | |
| Debt Issued | $0 | $173M | $0 | $0 | $0 | $0 | $25M | $0 | $25M | $10M | $39M | $0 | $0 | $0 | |
| Net Debt Issued | · | $-56M | · | · | · | $0 | · | · | · | $10M | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | |
| Financing Cash Flow | $4M | $67M | $-97.0K | $-271.0K | $80.0K | $0 | $26M | $122M | $25M | $10M | $212M | $13.0K | $142M | $14M | |
| Net Change in Cash | $2M | $51M | $-5M | $-14M | $-63M | $-85M | $-37M | $58M | $-46M | $-59M | $168M | $-33M | $119M | $-26M | |
| Free Cash Flow | · | $-16M | · | · | · | $-85M | · | · | · | $-69M | · | · | · | $-40M |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.7% | 79.4% | · | 87.5% | 87.2% | 86.9% | · | 85.6% | 81.2% | 77.7% | · | · | · | · | |
| Operating Margin | -5.3% | -26.6% | · | -30.9% | -151.7% | -276.5% | · | -433.0% | -1055.4% | -3658.7% | · | · | · | · | |
| Net Margin | -23.7% | -52.1% | · | -60.6% | -191.9% | -330.7% | · | -523.3% | -1248.6% | -4333.3% | · | · | · | · | |
| EBITDA Margin | -5.3% | -26.4% | · | -30.9% | -151.7% | -275.9% | · | -433.0% | -1055.4% | -3647.5% | · | · | · | · | |
| ROA | -6.1% | -10.1% | · | -9.6% | -26.6% | -29.0% | · | -27.4% | -31.3% | -33.1% | · | -19.7% | -17.1% | -25.8% | |
| ROE | 4.7% | 9.0% | · | 9.8% | 23.7% | 38.7% | · | 83.5% | 84.6% | 69.4% | · | 195.7% | -772.9% | 145.0% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.2 | · | 2.2 | 2.4 | 3.6 | · | 5.7 | 6.5 | 7.8 | · | 9.5 | 12.0 | 9.7 | |
| Quick Ratio | 1.8 | 2.1 | · | 2.1 | 2.2 | 3.4 | · | 5.4 | 6.1 | 7.5 | · | 8.9 | 11.6 | 9.0 | |
| Debt / Equity | -0.5 | -0.5 | · | -0.5 | -0.5 | -0.6 | · | -0.9 | -0.7 | -1.0 | · | -5.6 | 5.6 | -1.1 | |
| LT Debt / Equity | -0.5 | -0.5 | · | -0.5 | -0.5 | -0.6 | · | -0.9 | -0.7 | -1.0 | · | -5.6 | 5.6 | -1.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -4.4 | -4.1 | · | -3.5 | -3.3 | -3.3 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.0 | 0.0 | · | · | · | · | |
| Inventory Turnover | 2.7 | 2.5 | · | 1.8 | 1.8 | 1.6 | · | 1.5 | 1.2 | 0.6 | · | · | · | · | |
| Receivables Turnover | 1.0 | 1.0 | · | 1.3 | 1.3 | 1.4 | · | 1.6 | 1.3 | 1.0 | · | · | · | · |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-4.30 | $-4.24 | · | $-5.95 | $-5.79 | $-4.86 | · | $-2.74 | $-3.99 | $-2.54 | · | $-0.31 | $0.31 | $-2.07 | |
| Revenue / Share | $0.89 | $0.71 | · | $0.67 | $0.55 | $0.40 | · | $0.25 | $0.13 | $0.03 | · | · | · | · | |
| Cash Flow / Share | · | $-0.19 | · | · | · | $-1.18 | · | · | · | $-1.18 | · | · | · | $-0.94 | |
| Cash / Share | $2.28 | $2.28 | · | $1.90 | $2.13 | $3.05 | · | $4.90 | $4.71 | $5.51 | · | $3.76 | $4.39 | $2.97 | |
| EPS (TTM) | $-1.25 | $-2.09 | · | $-3.76 | $-4.67 | $-5.18 | · | $-5.74 | $-5.18 | $-4.46 | · | $-3.82 | $-4.38 | $-4.87 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $240M | $205M | · | $147M | $114M | $82M | · | $26M | $10M | $3M | · | · | · | · | |
| Net Income TTM | $-99M | $-157M | · | $-275M | $-330M | $-346M | · | $-339M | $-297M | $-247M | · | $-177M | $-185M | $-195M | |
| Market Cap | $869M | $883M | · | $836M | $672M | $437M | · | $1.24B | $604M | $622M | · | $589M | $811M | $311M | |
| Enterprise Value | $851M | $865M | · | $908M | $728M | $428M | · | $1.08B | $502M | $448M | · | $475M | $660M | $278M | |
| P/E | -8.7 | -5.3 | · | -3.1 | -2.1 | -1.2 | · | -3.1 | -2.0 | -2.4 | · | -2.7 | -3.3 | -1.5 | |
| P/S | 3.6 | 4.3 | · | 5.7 | 5.9 | 5.3 | · | 47.0 | 60.9 | 239.6 | · | · | · | · | |
| P/B | -2.5 | -2.6 | · | -2.0 | -1.7 | -1.3 | · | -6.6 | -2.6 | -4.2 | · | -33.1 | 46.1 | -3.4 | |
| P / Tangible Book | · | · | · | · | · | · | · | · | · | · | · | · | 46.1 | · | |
| P / Cash Flow | · | -56.4 | · | · | · | -5.1 | · | · | · | -9.0 | · | · | · | -7.8 | |
| EV / Revenue | 3.6 | 4.2 | · | 6.2 | 6.4 | 5.2 | · | 41.0 | 50.6 | 172.8 | · | · | · | · | |
| Earnings Yield | -11.5% | -18.8% | · | -31.9% | -48.7% | -82.6% | · | -31.8% | -50.3% | -42.0% | · | -36.8% | -30.6% | -68.2% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $175M | $55M | $682.0K | $0 | · |
| 毛利率 % | 87.1% | 85.6% | 75.5% | · | · |
| 营业利润率 % | -91.4% | -502.2% | -24532.5% | · | · |
| 净收入 | $-221M | $-334M | $-202M | $-198M | $-144M |
| 稀释后每股收益 (EPS) | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | -0.5 | -0.8 | -1.9 | -1.3 | 1.2 |
| 流动比率 | 1.7 | 4.2 | 10.2 | 6.1 | 9.9 |
| 速动比率 | 1.6 | 3.9 | 9.9 | 5.9 | 9.7 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $-167M | $-267M | $-139M | $-148M | $-149M |
机构持有人 (13F) 176 家申报者 · $818.8M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
176
持有价值
$818.8M
新仓位
26
已退出持仓
31
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 26 (-13 与上一季度对比) | 31 (-4 与上一季度对比) | 59 (-16 与上一季度对比) | 52 (+12 与上一季度对比) | +5.7M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | $135261406 | 12466489 | 16.52% | 股份 |
| Medicxi Ventures Management (Jersey) Ltd | $80990606 | 7464572 | 9.89% | 股份 |
| VANGUARD GROUP INC | $52709931 | 3177211 | 6.44% | 股份 |
| BlackRock, Inc. | $49097648 | 4525129 | 6.00% | 股份 |
| Invesco Ltd. | $43722581 | 4029731 | 5.34% | 股份 |
| Carlyle Group Inc. | $37940367 | 3496808 | 4.63% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $36627799 | 3375834 | 4.47% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $28827842 | 2656944 | 3.52% | 股份 |
| FRANKLIN RESOURCES INC | $21383482 | 1970828 | 2.61% | 股份 |
| NEA Management Company, LLC | $21267834 | 1960169 | 2.60% | 股份 |
| 683 Capital Management, LLC | $20072501 | 1850000 | 2.45% | 股份 |
| GOLDMAN SACHS GROUP INC | $19291647 | 1778032 | 2.36% | 股份 |
| STATE STREET CORP | $17211605 | 1586323 | 2.10% | 股份 |
| Catalys Pacific, LLC | $16208316 | 1493854 | 1.98% | 股份 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $15871000 | 1462738 | 1.94% | 股份 |
| WASATCH ADVISORS LP | $14897577 | 1340916 | 1.82% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $14277589 | 1315687 | 1.74% | 股份 |
| Ensign Peak Advisors, Inc | $11413256 | 1051913 | 1.39% | 股份 |
| Propel Bio Management, LLC | $11396384 | 1050358 | 1.39% | 股份 |
| Point72 Asset Management, L.P. | $11090794 | 1022193 | 1.35% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $8643446 | 796631 | 1.06% | 股份 |
| SummitTX Capital, L.P. | $8566618 | 789550 | 1.05% | 股份 |
| HSBC HOLDINGS PLC | $7701936 | 709695 | 0.94% | 股份 |
| MARSHALL WACE, LLP | $7227078 | 666090 | 0.88% | 股份 |
| EcoR1 Capital, LLC | $6781250 | 625000 | 0.83% | 股份 |
| PERCEPTIVE ADVISORS LLC | $5772200 | 532000 | 0.70% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $5631975 | 519076 | 0.69% | 股份 |
| CITADEL ADVISORS LLC | $5216680 | 480800 | 0.64% | 买入期权 |
| NORTHERN TRUST CORP | $4972565 | 458301 | 0.61% | 股份 |
| StepStone Group LP | $4689364 | 422085 | 0.57% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4547170 | 419094 | 0.56% | 股份 |
| Woodline Partners LP | $4004214 | 369052 | 0.49% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $3847117 | 354573 | 0.47% | 股份 |
| AMERIPRISE FINANCIAL INC | $3189673 | 293979 | 0.39% | 股份 |
| JPMORGAN CHASE & CO | $2991978 | 275251 | 0.37% | 股份 |
| Simplify Asset Management Inc. | $2704547 | 249267 | 0.33% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $2456440 | 226400 | 0.30% | 股份 |
| JANE STREET GROUP, LLC | $2307860 | 212706 | 0.28% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $2281755 | 210300 | 0.28% | 买入期权 |
| UBS Group AG | $2219618 | 204573 | 0.27% | 股份 |
| NewEdge Advisors, LLC | $2212988 | 203962 | 0.27% | 股份 |
| Avidity Partners Management LP | $2170000 | 200000 | 0.27% | 股份 |
| MORGAN STANLEY | $2169013 | 199909 | 0.26% | 股份 |
| Jump Financial, LLC | $2081746 | 191866 | 0.25% | 股份 |
| Opaleye Management Inc. | $2013641 | 185589 | 0.25% | 股份 |
| CITADEL ADVISORS LLC | $2006176 | 184901 | 0.25% | 股份 |
| Trexquant Investment LP | $1886641 | 173884 | 0.23% | 股份 |
| Jones Hill Capital LP | $1752123 | 161486 | 0.21% | 股份 |
| Bank of New York Mellon Corp | $1652595 | 152313 | 0.20% | 股份 |
| WELLS FARGO & COMPANY/MN | $1649221 | 152002 | 0.20% | 股份 |
激进投资者及 5%+ 股东 5 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C., Frazier Life Sciences XII, L.P., FHMLS XII, L.P., FHMLS XII, L.L.C., James N. Topper, Patrick J. Heron ×3 申报 | 2025年11月4日 | 8.60% | 修订 | · | SEC |
| Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C., Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences Public Overage Fund, L.P., FHMLSP Overage, L.P., FHMLSP Overage, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., James N. Topper, Patrick J. Heron, Albert Cha, James Brush, Daniel Estes ×8 申报 | 2024年8月22日 | · | 初始申报 | 被动投资 | SEC |
| Takeda Pharmaceutical Company Limited ×3 申报 | 2024年4月10日 | · | 初始申报 | · | SEC |
| Frazier Life Sciences IX, L.P ., FHMLS IX, L.P., FHMLS IX, L.L.C., Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences Public Overage Fund, L.P., FHMLSP Overage, L.P., FHMLSP Overage, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., James N. Topper, Patrick J. Heron, Albert Cha, James Brush, Daniel Estes | 2023年5月26日 | · | 初始申报 | 被动投资 | SEC |
| S.S. OR ×5 申报 | 2021年11月12日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 20 位内幕人士 · 9 位高管 · 12 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Steven L Basta | President and CEO | 2026年2月10日 F | 373315 | 0 | 0 | $0 |
| Molly Henderson | CFO and CBO | 2025年4月7日 S | 89868 | 0 | 0 | $0 |
| Todd P. Branning | Chief Financial Officer | 2021年1月28日 A | · | 0 | 0 | $0 |
| Terrie Curran | President and Chief Executive | 2025年2月27日 A | 360465 | 0 | 0 | $0 |
| Azmi Nabulsi | Chief Operating Officer | 2025年2月27日 A | 312590 | 0 | 0 | $0 |
| Robert Charles Breedlove | Principal Accounting Officer | 2026年9月3日 F | 59465 | 0 | 1 | $-7079 |
| Anne Marie Cook | Chief Legal Off. & Corp. Sec. | 2026年2月10日 F | 88660 | 0 | 0 | $0 |
| Sanjeev Narula | Chief Financial & Bus. Officer | 2026年1月2日 A | 226715 | 0 | 0 | $0 |
| Anthony J. Guzzo | VP, Chief Accounting Officer | 2022年1月19日 A | 8399 | 0 | 0 | $0 |
| Asit Parikh | 董事 | 2026年5月22日 G | 148500 | 0 | 0 | $0 |
| Mark Stenhouse | 董事 | 2026年5月19日 A | 54122 | 0 | 0 | $0 |
| Theodore R Schroeder | 董事 | 2026年5月19日 A | 45122 | 0 | 0 | $0 |
| James N. Topper | 董事 | 2026年5月19日 A | 66718 | 0 | 0 | $0 |
| Frank Karbe | 董事 | 2026年5月19日 A | 91622 | 0 | 0 | $0 |
| Michael F Cola | 董事 | 2026年5月19日 A | 63920 | 0 | 0 | $0 |
| Heidi Kunz | 董事 | 2026年5月19日 A | 54122 | 0 | 0 | $0 |
| David A Socks | 董事 | 2024年5月23日 A | 19500 | 0 | 0 | $0 |
| Tadataka Yamada | 董事 | 2021年5月21日 A | · | 0 | 0 | $0 |
| Jonathan S. Edwards | 董事 | 2019年10月29日 C | 47984 | 0 | 0 | $0 |
| Takeda Pharmaceutical Company Limited | · | 2024年1月24日 S | 3755583 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 24 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1.16% | 130873 NS | 2026年7月31日 | N-PORT |
| PILL · Direxion Shares ETF Trust | 0.64% | 15083 NS | 2026年7月31日 | N-PORT |
| IWC · iShares Trust | 0.10% | 167720 SH | 2026年9月11日 | 每日 |
| IHE · iShares Trust | 0.10% | 187890 SH | 2026年9月11日 | 每日 |
| VFMO · VANGUARD WELLINGTON FUND | 0.04% | 78352 SH | 2026年8月19日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.04% | 5742 SH | 2026年10月2日 | 每日 |
| IBB · iShares Trust | 0.04% | 439273 SH | 2026年9月11日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 283184 SH | 2026年8月19日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 30521 SH | 2026年8月19日 | 每日 |
| ISCG · iShares Trust | 0.02% | 18633 SH | 2026年9月11日 | 每日 |
| RSSL · Global X Funds | 0.01% | 23493 NS | 2026年7月31日 | N-PORT |
| IWM · iShares Trust | 0.01% | 1255887 SH | 2026年9月11日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 586438 SH | 2026年8月19日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.01% | 15003 SH | 2026年8月19日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.01% | 148237 SH | 2026年8月19日 | 每日 |
| IWO · iShares Trust | 0.01% | 132821 SH | 2026年9月11日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 22619 NS | 2026年7月31日 | N-PORT |
| WSML · iShares Trust | 0.00% | 2597 SH | 2026年9月11日 | 每日 |
| ITOT · iShares Trust | 0.00% | 79252 SH | 2026年9月11日 | 每日 |
| IWV · iShares Trust | 0.00% | 9388 SH | 2026年9月3日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 2007668 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3478 SH | 2026年8月19日 | 每日 |
| IWN · iShares Trust | · | 330692 SH | 2026年9月11日 | 每日 |
| ISCB · iShares Trust | · | 2641 SH | 2026年9月11日 | 每日 |
PHAT 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 17 位分析师
买入
中位数目标
$21.00
+203.5%
6 35.3%
强烈买入
9 52.9%
买入
2 11.8%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
11 位分析师 · 2026-09-29平均目标 $20.45 +195.6%
← 低于所有目标
当前价格 $6.92
最低$10.00
平均值$20.45
最高$29.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| PHAT | $1.18B | -5.5 | 216.9% | -126.4% | 52.4% | 87.1% |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | · |
| AQST | $788M | -8.3 | -22.6% | -188.1% | 157.7% | · |
| ZVRA | $509M | 6.6 | 350.9% | 78.2% | 61.2% | · |
| CRMD | $922M | 5.7 | 617.0% | 52.3% | 52.1% | 88.5% |
| CTNM | · | -5.3 | · | · | -27.7% | · |
| ARVN | $753M | -10.4 | -0.30% | -30.8% | -15.5% | · |
| EOLS | $432M | -8.3 | 11.6% | -17.4% | 247.3% | 66.3% |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 七月 30, 2026 申报